From the Editors of PharmAsia News September 22, 2009
In this BioPharma Today feature, the editors of PharmAsia News take a closer look each week at the most important biopharma developments from China, India, Japan, and the Pacific Rim.
Read today's features...
From the Editors of PharmAsia News September 22, 2009
PERTH, Australia – With China's entire healthcare environment set to undergo rapid-fire change, propelled by system-wide healthcare reforms, players that are the nimblest at adapting to or even promoting the transformation will emerge as the strongest winners."The best way to be commercially successful here is to help the Chinese government achieve its objectives in health reforms," said Ronny Krishana, senior director of strategy and business development at Pfizer China's headquarters in Beijing.
With the dual goals of being a model corporate citizen and expanding its geographic and demographic reach across China, Pfizer has launched a number of test projects over the last 12 months that could ultimately push forward the country's health system reforms and the company's own ambitions.
[Editor’s note: Don't miss the PharmAsia Summit Oct. 26-28 in San Francisco where Pfizer's Ronny Krishana will share his experience about maximizing the market opportunities in China. Click here for more information.
In India … Lupin is making the switch from pure generic drugs in the U.S. to a patented and branded play faster than many analysts expected. Lupin made an audacious $38.61 million bid for bankruptcy-threatened Oscient Pharma's top cardiovascular drug Antara (fenofibrate), and finally clinched the deal while outpacing at least three other generic rivals. With this latest addition, Lupin has three branded drugs in the U.S. market, Suprax (cefixime), its anti-infective leading the portfolio, followed by the recently purchased intra-nasal steroid Allernaze (triamcinolone). Click here for more information.
And in South Korea … The Ministry for Health, Welfare and Family Affairs plans to unveil by the end of next month its new drug reimbursement pricing system, which will lower profits for higher priced generics and still reward hospitals for buying drugs at lower prices. "Basically, the new pricing system will be focused on extending benefits or incentives to hospitals buying drugs at low cost," Kim Sung-Tae, deputy director of the Ministry's Pharmaceutical Benefits Division, told PharmAsia News. Click here for more information.
Join senior level biopharma execs from China & India at the PharmAsia Summit – Oct. 26-28, 2009, San Francisco
Not a subscriber? Click here to start your 30-day, risk-free trial of PharmAsia News – Immediate business intelligence from China, India, Japan and the Pacific Rim, from the publishers of "The Pink Sheet."
